ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Research Study for Patients With Overactive Bladder

Phase 2

Completed

Conditions: Overactive Bladder
Urinary Incontinence

Interventions: Drug: Placebo
Biological: botulinum toxin Type A

First Posted Date: 2005-09-15

Last Posted Date: 2013-11-06

Lead Sponsor: Allergan

Target Recruit Count: 313

Registration Number: NCT00168454

A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Phase 2

Completed

Conditions: Postherpetic Neuralgia

First Posted Date: 2005-09-15

Last Posted Date: 2011-05-30

Lead Sponsor: Allergan

Target Recruit Count: 117

Registration Number: NCT00168441

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Phase 3

Completed

Conditions: Hyperhidrosis

First Posted Date: 2005-09-15

Last Posted Date: 2011-05-30

Lead Sponsor: Allergan

Target Recruit Count: 193

Registration Number: NCT00168402

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Phase 3

Completed

Conditions: Macular Edema
Retinal Vein Occlusion

Interventions: Drug: 700 µg Dexamethasone
Other: Sham Injection
Drug: 350 µg Dexamethasone

First Posted Date: 2005-09-15

Last Posted Date: 2019-04-23

Lead Sponsor: Allergan

Target Recruit Count: 599

Registration Number: NCT00168324

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Dexamethasone
Other: Sham

First Posted Date: 2005-09-15

Last Posted Date: 2014-08-04

Lead Sponsor: Allergan

Target Recruit Count: 554

Registration Number: NCT00168337

Memantine in Patients With Chronic Glaucoma

Phase 3

Completed

Conditions: Open-Angle Glaucoma

First Posted Date: 2005-09-15

Last Posted Date: 2010-11-04

Lead Sponsor: Allergan

Target Recruit Count: 1179

Registration Number: NCT00168350

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Phase 3

Completed

Conditions: Retinal Vein Occlusion
Macular Edema

Interventions: Drug: 700 µg Dexamethasone
Drug: 350 µg Dexamethasone
Other: Sham Injection

First Posted Date: 2005-09-15

Last Posted Date: 2019-04-23

Lead Sponsor: Allergan

Target Recruit Count: 668

Registration Number: NCT00168298

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Phase 4

Completed

Conditions: Hyperhidrosis

Interventions: Biological: Botulinum Toxin Type A

First Posted Date: 2005-09-15

Last Posted Date: 2008-09-29

Lead Sponsor: Allergan

Target Recruit Count: 424

Registration Number: NCT00168480

A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis

Phase 4

Completed

Conditions: Hyperhidrosis

Interventions: Biological: Botulinum Toxin Type A

First Posted Date: 2005-09-15

Last Posted Date: 2008-09-29

Lead Sponsor: Allergan

Target Recruit Count: 144

Registration Number: NCT00168415

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Dexamethasone
Other: Sham

First Posted Date: 2005-09-15

Last Posted Date: 2014-08-04

Lead Sponsor: Allergan

Target Recruit Count: 494

Registration Number: NCT00168389

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy